An in situ depot for the sustained release of a TLR7/8 agonist in combination with a TGFβ inhibitor promotes anti-tumor immune responses.
Jensen SB, Jæhger DE, Serrano-Chávez E, Halldórsdóttir HR, Engel TB, Jørgensen JS, Björgvinsdóttir UJ, Kostrikov S, Scheeper MJ, Ringgaard L, Bruun LM, Stavnsbjerg C, Christensen E, Bak M, Thuroczy J, Balogh L, Jensen ATI, Melander F, Kjaer A, Henriksen JR, Hansen AE, Andresen TL.
Jensen SB, et al. Among authors: christensen e.
Nat Commun. 2024 Sep 3;15(1):7687. doi: 10.1038/s41467-024-50967-w.
Nat Commun. 2024.
PMID: 39227589
Free PMC article.